200 related articles for article (PubMed ID: 1326622)
21. [Comparison of the antagonistic effects of 6 beta-naltrexol and naltrexone against morphine analgesia].
Yan LD; Gong ZH; Yao XJ; Qin BY
Yao Xue Xue Bao; 2003 Aug; 38(8):578-81. PubMed ID: 14628446
[TBL] [Abstract][Full Text] [Related]
22. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
[TBL] [Abstract][Full Text] [Related]
23. Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism.
Jiang Q; Seyed-Mozaffari A; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1995 May; 273(2):680-8. PubMed ID: 7752070
[TBL] [Abstract][Full Text] [Related]
24. Clocinnamox dose-dependently antagonizes morphine-analgesia and [3H]DAMGO binding in rats.
Paronis CA; Woods JH
Eur J Pharmacol; 1997 Oct; 337(1):27-34. PubMed ID: 9389377
[TBL] [Abstract][Full Text] [Related]
25. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
[TBL] [Abstract][Full Text] [Related]
26. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action.
Millan MJ; Członkowski A; Lipkowski A; Herz A
J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723
[TBL] [Abstract][Full Text] [Related]
27. Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands.
Zimmerman DM; Leander JD; Reel JK; Hynes MD
J Pharmacol Exp Ther; 1987 May; 241(2):374-8. PubMed ID: 3033213
[TBL] [Abstract][Full Text] [Related]
28. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
29. In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice.
Raehal KM; Lowery JJ; Bhamidipati CM; Paolino RM; Blair JR; Wang D; Sadée W; Bilsky EJ
J Pharmacol Exp Ther; 2005 Jun; 313(3):1150-62. PubMed ID: 15716384
[TBL] [Abstract][Full Text] [Related]
30. The effect of the irreversible mu-opioid receptor antagonist clocinnamox on morphine potency, receptor binding and receptor mRNA.
Chan K; Brodsky M; Davis T; Franklin S; Inturrisi CE; Yoburn BC
Eur J Pharmacol; 1995 Dec; 287(2):135-43. PubMed ID: 8749027
[TBL] [Abstract][Full Text] [Related]
31. 3-Alkyl ethers of clocinnamox: delayed long-term mu-antagonists with variable mu efficacy.
Husbands SM; Sadd J; Broadbear JH; Woods JH; Martin J; Traynor JR; Aceto MD; Bowman ER; Harris LS; Lewis JW
J Med Chem; 1998 Aug; 41(18):3493-8. PubMed ID: 9719602
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
Zernig G; Burke T; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Oct; 279(1):23-31. PubMed ID: 8858971
[TBL] [Abstract][Full Text] [Related]
33. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F
J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958
[TBL] [Abstract][Full Text] [Related]
34. Analgesic activity and pharmacological characterization of N-[1-phenylpyrazol-3-yl]-N-[1-(2-phenethyl)-4-piperidyl] propenamide, a new opioid agonist acting peripherally.
Goicoechea C; Sánchez E; Cano C; Jagerovic N; Martín MI
Eur J Pharmacol; 2008 Oct; 595(1-3):22-9. PubMed ID: 18706410
[TBL] [Abstract][Full Text] [Related]
35. Prostaglandin E2-induced thermal hyperalgesia and its reversal by morphine in the warm-water tail-withdrawal procedure in rhesus monkeys.
Negus SS; Butelman ER; Al Y; Woods JH
J Pharmacol Exp Ther; 1993 Sep; 266(3):1355-63. PubMed ID: 8371142
[TBL] [Abstract][Full Text] [Related]
36. Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats.
Paronis CA; Holtzman SG
J Pharmacol Exp Ther; 1992 Jul; 262(1):1-9. PubMed ID: 1625189
[TBL] [Abstract][Full Text] [Related]
37. Analgesia produced by E-2078, a systemically active dynorphin analog, in mice.
Nakazawa T; Furuya Y; Kaneko T; Yamatsu K; Yoshino H; Tachibana S
J Pharmacol Exp Ther; 1990 Mar; 252(3):1247-54. PubMed ID: 1969472
[TBL] [Abstract][Full Text] [Related]
38. Magnitude of tolerance to fentanyl is independent of mu-opioid receptor density.
Chan KW; Duttory A; Yoburn BC
Eur J Pharmacol; 1997 Jan; 319(2-3):225-8. PubMed ID: 9042594
[TBL] [Abstract][Full Text] [Related]
39. In vivo apparent pA2 analysis in rats treated with either clocinnamox or morphine.
Walker EA; Richardson TM; Young AM
Psychopharmacology (Berl); 1996 May; 125(2):113-9. PubMed ID: 8783384
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of morphine tolerance by processed Aconiti tuber is mediated by kappa-opioid receptors.
Shu H; Arita H; Hayashida M; Chiba S; Sekiyama H; Hanaoka K
J Ethnopharmacol; 2006 Jun; 106(2):263-71. PubMed ID: 16446067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]